Becton Dickinson and Company Trading Volume Plummets 72.31% to 336th Position Amid Stock Price Decline

On March 24, 2025, Becton Dickinson and Company (BDX) experienced a significant decline in trading volume, with a total of 2.78 billion shares traded, marking a 72.31% decrease from the previous day. This drop in volume placed BDX at the 336th position in terms of trading volume for the day. The stock price of BDX also decreased by 0.45%, marking the second consecutive day of decline, with a total decrease of 1.15% over the past two days.

Becton Dickinson and Company has made significant progress in its clinical trial for the bioabsorbable GalaFLEX LITE scaffold. This advancement aims to enhance outcomes in breast implant revision surgeries and improve patient satisfaction. The successful completion of this trial could potentially drive the stock price higher, as investors anticipate the positive impact on the company's revenue and market position.